摘要
目的:观察白三烯受体拮抗剂孟鲁司特治疗儿童过敏性紫癜性肾炎(HSPN)的疗效。方法:67例儿童过敏性紫癜性肾炎患儿随机分为两组,对照组32例采用常规综合治疗,治疗组35例在常规综合治疗基础上加服孟鲁司特咀嚼片,≥10岁10mg/d,<10岁5mg/d,疗程为1个月。测定治疗前后血和尿中白三烯水平的变化,并观察临床效果。结果:治疗组总有效率(97.1%)优于对照组(84.4%)(χ2=3.24,P>0.05),但各组治疗前后及两组治疗后之间的白三烯水平比较差异均有统计学意义(P<0.01)。结论:白三烯参与了HSPN的发病过程,用白三烯受体拮抗剂孟鲁司特治疗HSPN有效。
Objective： To investigate the clinical effect of montelukast in treating Henoch-Schonlein purpura nephritis （HSPN） in children. Methods： Sixty-seven children with HSPN were randomly divided into two groups. The control group （32 cases） was treated with conventional medication. The treatment group （35 cases） was treated with montelukast sodium （≥ 10 year-old 10 mg/d, 〈 10 year-old 5 mg/d） for one month in addition. The leukotrienes （LTs） levels in serum and urinary were observed before and post treatment and the curative effects were got. Results： The total effective rate of the treatment group was 97. 1%, better than that of the contrl group （84.4%） （Х^2 = 3.34, P 〉 0.05 ）. There was significant difference in the LTs level between the two groups before and after the treatment （P 〈 0.01 ）. Conclusions： There is a close relationship between LTs expression in HSPN. Leukotrienes antagonists montelukast sodium is effective in treatment of HSPN.
出处
《儿科药学杂志》
CAS
2009年第2期13-15,共3页
Journal of Pediatric Pharmacy
关键词
孟鲁司特
过敏性紫癜
肾炎
白三烯
儿童
Montelukast
Purpura, Schonlein-Henoch
Nephritis
Leukotrienes
Child
